Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2010 · 1 min read
In brief
In brief
This case report demonstrates successful sirolimus therapy in a pediatric TSC patient with recurrent chest wall fibromatosis and bilateral multifocal renal cell carcinoma. mTOR inhibition achieved substantial tumor response within 6 months, avoiding bilateral nephrectomy while preserving renal function with minimal adverse effects.
Written by the GCMD Library team from the article.
Statements in this article
A male patient with tuberous sclerosis complex developed chest wall fibromatosis and bilateral multifocal renal cell carcinoma.
The fibromatosis tumor recurred 5 years after initial resection during infancy.
The more extensively affected right kidney was resected due to bilateral renal cell carcinoma.
Sirolimus was used to avoid bilateral nephrectomies in this patient.
Within 6 months of sirolimus therapy, the fibromatosis and remaining renal cell carcinoma tumors responded substantially with minimal adverse effects.